Vitamin D Repletion Before Starting Bisphosphonates

Introduction to Vitamin D Repletion

• The American College of Physicians recommends correcting vitamin D deficiency before initiating bisphosphonate therapy to prevent hypocalcemia and optimize treatment efficacy, particularly for intravenous formulations 1, 2
• Vitamin D deficiency should be corrected prior to initiation of bisphosphonates therapy because deficiency may attenuate the efficacy of bisphosphonates and increase the risk of bisphosphonate-related hypocalcemia, according to the National Comprehensive Cancer Network 1

Why Vitamin D Repletion is Mandatory

• Hypocalcemia has been specifically reported in patients with unrecognized vitamin D deficiency who started intravenous bisphosphonates, as noted by the Journal of the National Comprehensive Cancer Network 2
• The risk of hypocalcemia is highest with IV formulations, such as zoledronic acid and ibandronate, due to rapid bone uptake and acute suppression of bone turnover, as reported by the Clinical Infectious Diseases journal 1, 2
• Vitamin D deficiency reduces bisphosphonate efficacy by impairing calcium absorption and bone mineralization, according to the Clinical Infectious Diseases journal 1

Target Vitamin D Levels Before Starting Treatment

• The Endocrine Society recommends achieving serum 25(OH)D level of ≥32 ng/mL before initiating bisphosphonates 1
• Some experts, including those from the Clinical Infectious Diseases journal, recommend levels in the 40-50 ng/mL range for optimal bone health 1

Vitamin D Repletion Regimens

• For 25(OH)D concentrations >15 ng/mL, the Clinical Infectious Diseases journal recommends Vitamin D3 (cholecalciferol) 2,000 IU daily for 12 weeks, then 1,000-2,000 IU daily for maintenance 1
• For 25(OH)D concentrations <15 ng/mL or with secondary hyperparathyroidism, the Clinical Infectious Diseases journal recommends Vitamin D2 (ergocalciferol) 50,000 IU weekly for 8-12 weeks, then monthly thereafter 1

Ongoing Calcium and Vitamin D During Bisphosphonate Therapy

• The American College of Rheumatology recommends concurrent supplementation with calcium (1,000-1,200 mg/day) and vitamin D (600-800 IU/day) for maintenance after repletion, as reported by the Arthritis Care & Research journal 3

Clinical Algorithm for Starting Bisphosphonates

• The Clinical Infectious Diseases journal recommends checking baseline 25(OH)D level before prescribing any bisphosphonate, and initiating repletion regimen based on severity if 25(OH)D <32 ng/mL 1
• The Arthritis Care & Research journal recommends starting bisphosphonate with concurrent calcium (1,000-1,200 mg/day) and vitamin D (600-800 IU/day) once 25(OH)D ≥32 ng/mL 3, 1

Special Considerations

• The National Comprehensive Cancer Network notes that oral bisphosphonates carry lower hypocalcemia risk than IV formulations, but vitamin D optimization still improves efficacy 1
• The Clinical Infectious Diseases journal recommends higher vitamin D doses for patients with malabsorption, chronic kidney disease, or those on glucocorticoids 1

Treatment Options for Osteoporosis with History of Vertebral Fractures

Introduction to Treatment Algorithm

• The American College of Rheumatology recommends intravenous bisphosphonates as first-line alternative therapy for patients with osteoporosis and a history of vertebral fractures who cannot tolerate oral bisphosphonates, followed by teriparatide and then denosumab if IV bisphosphonates are not appropriate 4, 5

Treatment Options

• Intravenous bisphosphonates, such as zoledronic acid or ibandronate, are the preferred first alternative due to their established efficacy in reducing vertebral, non-vertebral, and hip fractures in patients with osteoporosis and a history of vertebral fractures 6, 4
• Teriparatide, an anabolic agent, should be considered if bisphosphonate therapy is not appropriate for patients with severe osteoporosis and multiple vertebral fractures 4, 5, 7
• Denosumab, a RANKL inhibitor, may be considered if neither oral/IV bisphosphonates nor teriparatide are appropriate for patients with osteoporosis and a history of vertebral fractures 4, 5
• Raloxifene may be considered for postmenopausal women with osteoporosis and a history of vertebral fractures when none of the above medications are appropriate, although it has less robust evidence for fracture prevention 4, 5

Calcium and Vitamin D Supplementation

• All patients with osteoporosis should receive calcium (1000-1200 mg/day) and vitamin D (600-800 IU/day) supplementation regardless of pharmacological treatment to support bone health 4, 7
• Target serum 25(OH)D level should be ≥20 ng/mL, with some experts recommending 30-50 ng/mL for patients with osteoporosis 6, 8

Monitoring and Follow-up

• Reassessment of fracture risk should be performed every 1-3 years for patients with osteoporosis and a history of vertebral fractures 9
• Earlier reassessment is recommended for patients with very high doses of glucocorticoids or history of osteoporotic fractures 9

Special Considerations

• Intravenous bisphosphonates are not recommended in patients with creatinine clearance <30 mL/min due to renal risk 8
• Osteonecrosis of the jaw is rare (<1 case per 100,000 person-years) but should be considered, especially in patients requiring dental work 6

Lifestyle Modifications

• All patients with osteoporosis should be advised on lifestyle modifications including smoking cessation, regular weight-bearing or resistance training exercise, limiting alcohol intake to 1-2 alcoholic beverages per day, and maintaining weight in the recommended range 4, 10

Vitamin D Repletion Before Bisphosphonate Therapy

Baseline Testing and Supplementation

• The American College of Rheumatology recommends measuring serum creatinine before initiating bisphosphonate therapy, as bisphosphonates are contraindicated if CrCl <30 mL/min, and continuing vitamin D 800-1,000 IU daily for maintenance, along with calcium 1,000-1,200 mg daily 11

Concurrent Supplementation

• The American College of Rheumatology suggests continuing vitamin D 800-1,000 IU daily for maintenance, and adding calcium 1,000-1,200 mg daily, when starting bisphosphonate therapy 11

Contraindications to Bisphosphonates

Absolute Contraindications

• Patients with esophageal abnormalities that delay esophageal emptying should receive IV bisphosphonates instead of oral formulations, as recommended by the American College of Rheumatology 12
• Patients who cannot stand or sit upright for at least 30 minutes after taking oral bisphosphonates are contraindicated from using these formulations, and IV bisphosphonates are the preferred alternative, according to the American College of Rheumatology 12

Relative Contraindications and Special Precautions

• The American College of Rheumatology recommends that women of childbearing potential require careful counseling about the long-term skeletal retention of bisphosphonates 12
• Patients requiring invasive dental procedures have increased risk of osteonecrosis of the jaw (ONJ), with an incidence of 0.01-0.3% overall, and risk increases with longer treatment duration, as reported by the American College of Internal Medicine 13, 14
• Prior atypical femoral fracture is a relative contraindication to continuing or restarting bisphosphonates, with risk increasing with treatment duration beyond 5 years, according to the American College of Internal Medicine 13, 14

Alternative Therapies When Bisphosphonates Are Contraindicated

• The American College of Internal Medicine recommends denosumab as the second-line agent for both postmenopausal women (moderate-certainty evidence) and men (low-certainty evidence) when bisphosphonates are contraindicated 13, 14
• For glucocorticoid-induced osteoporosis when oral bisphosphonates are inappropriate, the preference order is: IV bisphosphonates, then teriparatide, then denosumab, then raloxifene (postmenopausal women only), as recommended by the American College of Rheumatology 12

Bisphosphonate Therapy for Osteoporotic Vertebral Wedging Fractures

Indications for Treatment

• Initiate bisphosphonate therapy in post‑menopausal women or men > 65 years who have anterior vertebral wedging ≥ 20 % consistent with a fragility fracture, because this denotes established osteoporosis with a prevalent vertebral fracture—a strong indication for pharmacologic treatment to prevent subsequent fractures. 15, 16
• A vertebral fracture, even when asymptomatic, is a clinical sentinel event that markedly raises the risk of future vertebral, hip, and non‑vertebral fractures. 16
• Individuals with a single vertebral fracture have an approximately 5‑fold higher risk of another vertebral fracture and a 2‑ to 3‑fold higher risk of hip fracture. 16
• The primary goal of therapy is fracture prevention, which directly improves mortality, morbidity, and health‑related quality of life. 16

First‑Line Oral Bisphosphonates

• Alendronate or risedronate should be prescribed as first‑line agents; both have demonstrated efficacy in reducing vertebral, non‑vertebral, and hip fractures in patients with prevalent vertebral fractures. 15, 16
• These agents are preferred because of their well‑established efficacy, favorable safety profile, low cost (generic availability), and extensive clinical experience. 16

Alternative Therapies When Oral Bisphosphonates Are Not Feasible

• Intravenous bisphosphonates (zoledronic acid once yearly or ibandronate every 3 months) are recommended for patients who cannot tolerate oral therapy, have esophageal disorders, malabsorption, dementia, or poor adherence. 16
• Denosumab (subcutaneous injection every 6 months) is a second‑line option when oral or IV bisphosphonates are unsuitable. 15
• Teriparatide (anabolic agent) is reserved for patients with very severe osteoporosis or multiple vertebral fractures. 16

Mandatory Calcium and Vitamin D Supplementation

• All patients receiving bisphosphonates should take calcium 1,000–1,200 mg daily (total from diet and supplements). 16
• Vitamin D 800–1,000 IU daily should be provided for maintenance after repletion; supplementation was incorporated in all major bisphosphonate trials that demonstrated fracture reduction. 16

Treatment Duration and Monitoring

• Bisphosphonates are prescribed for an initial 3–5 years, after which a reassessment determines the need for continuation or a drug holiday. 16, 17
• Patients who remain at high risk (multiple fractures, very low bone mineral density, ongoing glucocorticoid therapy) should continue treatment beyond 5 years. 16

Correct Administration of Oral Bisphosphonates & Safety Considerations

• Oral bisphosphonates must be taken with a full glass of water on an empty stomach, and patients should avoid eating or drinking for at least 30 minutes after ingestion. 17
• Rare but serious adverse effects include:
  
  • Osteonecrosis of the jaw (incidence < 1 per 100,000 person‑years), with highest risk after recent dental surgery; necessary dental work should be completed before starting therapy. 17
  • Acute phase reaction (fever, myalgias) after the first IV bisphosphonate infusion. 17

Practical Clinical Recommendations

• Do not delay treatment while awaiting additional testing or specialist referral; a vertebral fracture alone justifies immediate initiation of therapy. 16
• Do not assume that an anterior wedging ≥ 20 % is merely degenerative; after excluding trauma, malignancy, and infection, it represents an osteoporotic fracture that requires treatment. 16